Advertisements

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Stock Quote

Detailed Quote for Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
$ 1.35   0.12 (+9.76%) Volume: 343.07k 10:08 AM EDT Jun 19, 2018
Today 5d 1m 3m 1y more
Last Price
1.35
Change $
0.12
Change %
9.76%
Tick
  
Bid
1.32
Bid Size
8,000
Ask
1.35
Ask Size
7,700
Open
1.36
High
1.37
Low
1.2736
Prev Close
1.23
Last Trade
10:08
Volume
343.07k
52 Wk Hi
2.75
52 Wk Low
1.17999994
Market Cap
26.97m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
19,981,145
EPS (TTM)
-1.05999994
PE Ratio
N/A
Exchange
NYSE American
News and Media for Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
Sector News | Topic News
News for Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
Tue, Jun 19, 2018
9:16 AM Premarket Gainers as of 9:05 am (06/19/2018) - SeekingAlpha
7:00 AM Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial - Business Wire
Wed, Jun 13, 2018
6:00 PM Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up - SeekingAlpha
9:22 AM Premarket Gainers as of 9:05 am (06/13/2018) - SeekingAlpha
Tue, Jun 12, 2018
11:25 AM Nash players perk up on Galmed surge - SeekingAlpha
Mon, Jun 11, 2018
7:53 AM Can-Fite up 8% premarket on preclinical data for NASH candidate namodenoson - SeekingAlpha
7:00 AM Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson - Business Wire
Fri, Jun 01, 2018
7:02 AM Can-Fite Biopharma beats by $0.01, beats on revenue - SeekingAlpha
7:00 AM Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update - Business Wire
Wed, May 02, 2018
10:47 AM Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH - SeekingAlpha
Wed, Apr 25, 2018
9:00 AM AbbVie files U.S. marketing application for plaque psoriasis med risankizumab - SeekingAlpha
7:00 AM Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research' - Business Wire
Tue, Apr 24, 2018
1:09 PM Adenosine A3 Receptor Agonist-Namodenoson And NASH: Can-Fite Biopharma Is Fighting The Good Fight - SeekingAlpha
Fri, Apr 13, 2018
7:30 AM Wired News - CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018 - ACCESSWIRE IA
Mon, Apr 09, 2018
7:00 AM Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL) - Business Wire
Wed, Mar 28, 2018
7:00 AM Can-Fite to Present at the MicroCap Conference - Business Wire
Fri, Mar 23, 2018
9:23 AM Can-Fite Biopharma net loss improves in FY 2017 - SeekingAlpha
7:21 AM Can-Fite Biopharma reports FY results - SeekingAlpha
7:00 AM Can-Fite Reports 2017 Financial Results & Provides Clinical Update - Business Wire
Fri, Mar 16, 2018
10:25 AM Key events next week - healthcare - SeekingAlpha
More News for CANF >>

Tags for Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Research stocks or mutual funds related to Can-Fite Biopharma Ltd Sponsored ADR (Israel) by keywords or tags. Find companies that have a similar focus to CANF. The keywords below have been associated to CANF by either user submission or electronic means.